| 40.98 Delayed Data As of Aug 22 |  +0.29 / +0.71%Today’s Change | 36.41 Today|||52-Week Range 42.47 | +7.25% Year-to-Date |
| Glaxo Submits First Regulatory Application for Daprodustat Aug 22 / Zacks.com - Paid Partner Content | Should Value Investors Consider GlaxoSmithKline (GSK) Stock? Aug 13 / Zacks.com - Paid Partner Content |
| Better Buy: Eli Lilly vs. GlaxoSmithKline Aug 18 / MotleyFool.com - Paid Partner Content | AnaptysBio Prepares for a Potential Gear Shift Aug 10 / MotleyFool.com - Paid Partner Content |
| Ionis Pharmaceuticals Looks to Partners to Pay the Bills Aug 14 / MotleyFool.com - Paid Partner Content | Agenus (AGEN) Q2 Earnings Miss Estimates, Revenues Beat Aug 09 / Zacks.com - Paid Partner Content |
| Previous close | 40.69 |
| Today’s open | 40.82 |
| Day’s range | 40.80 - 41.09 |
| Volume | 2,201,130 |
| Average volume (3 months) | 2,389,491 |
| Market cap | $96.5B |
| Earnings growth (last year) | +143.10% |
| Earnings growth (this year) | -7.36% |
| Earnings growth (next 5 years) | +4.00% |
| Revenue growth (last year) | +5.72% |
| P/E ratio | 18.8 |
| Price/Sales | 2.31 |
| Price/Book | 17.14 |
| Today’s change | Today’s % change | |
|---|---|---|
| ABBVAbbVie | -0.02 | -0.03% |
| LLYEli Lilly and Co | +0.15 | +0.13% |
| SNYSanofi | -0.63 | -1.46% |
| NVONovo Nordisk | +0.88 | +1.70% |
| Next reporting date | October 23, 2019 |
| EPS forecast (this quarter) | $0.78 |
| Annual revenue (last year) | $41.1B |
| Annual profit (last year) | $4.8B |
| Net profit margin | 11.75% |
Sector Health Technology |
Industry Pharmaceuticals: Major |
Chief Executive Officer & Executive Director Emma Walmsley |
Chief Financial Officer & Executive Director Iain James Mackay |
Corporate headquarters Brentford, Greater London |
